Comparative Pharmacology
Head-to-head clinical analysis: CHILDREN S MOTRIN versus DIFLUNISAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHILDREN S MOTRIN versus DIFLUNISAL.
CHILDREN'S MOTRIN vs DIFLUNISAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis, thereby decreasing pain, fever, and inflammation.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) enzymes, reducing prostaglandin synthesis, thereby exerting analgesic, anti-inflammatory, and antipyretic effects.
200-400 mg orally every 6-8 hours as needed; maximum 1200 mg/day without prescription, extended release forms: 600-800 mg orally twice daily.
500 mg to 1000 mg orally initially, then 250 mg to 500 mg every 8 to 12 hours. Maximum daily dose: 1500 mg.
None Documented
None Documented
Clinical Note
moderateDiflunisal + Gatifloxacin
"Diflunisal may increase the neuroexcitatory activities of Gatifloxacin."
Clinical Note
moderateDiflunisal + Rosoxacin
"Diflunisal may increase the neuroexcitatory activities of Rosoxacin."
Clinical Note
moderateDiflunisal + Levofloxacin
"Diflunisal may increase the neuroexcitatory activities of Levofloxacin."
Clinical Note
moderateDiflunisal + Trovafloxacin
"Diflunisal may increase the neuroexcitatory activities of Trovafloxacin."
2-4 hours in children; prolonged in neonates and hepatic impairment.
8-12 hours (prolonged in renal impairment; clinical context: permits twice-daily dosing)
Renal (90%) as inactive metabolites and conjugates; fecal (<5%).
Renal (90% as glucuronide conjugates, <5% unchanged); biliary/fecal (<10%)
Category C
Category C
NSAID
NSAID